Objective  This study was designed to determine the effect of BAY 11-7082 on NF-~cB expression and tumor colony formation of prostate cancer cells.

  Methods  Cell cytotoxicity assay kit-8 was used to detect cell death and proliferation according to the protocol. Western blot and densitometry analysis were performed to compare the expression of NF-KB in the control group with that of BAY 11-7082, an NF-nB inhibitor that is used to treat prostate cancer cells. Immunofluorescent staining was also conducted to moni- tor NF-KB activation and translocation in the nucleus. The effects of BAY 11-7082 on colony formation were determined by counting the number of prostate cancer cell colonies.

  Results  The treatment of prostate cancer cell line PC-3 cells by BAY 11-7082 inhibited cell proliferation and formed few colonies. Similarly, NF-tcB protein level dramatically decreased. Its translocation in the nucleus and the activation in the PC-3 cells were disrupted because of the effects of BAY 11-7082.

  Conclusion  BAY 11-7082 can inhibit the aberrant activation of NF-κB in prostate cancer cells and reduce tumor metastasis. Therefore, BAY 11-7082 is a potential drug for the treatment of prostate cancer patients in clinical practice in the future.